Genital herpes simplex virus infection is a recurrent, lifelong disease with no cure. The strongest predictor for infection is a person's number of lifetime sex partners. The natural history includes first-episode mucocutaneous infection, establishment of latency in the dorsal root ganglion, and subsequent reactivation. Most infections are transmitted via asymptomatic viral shedding. Classic outbreaks consist of a skin prodrome and possible constitutional symptoms such as headache, fever, and inguinal lymphadenopathy. As the infection progresses, papules, vesicles on an erythematous base, and erosions appear over hours to days. These lesions usually crust, re-epithelialize, and heal without scarring. First-episode infections are more extensive: primary lesions last two to six weeks versus approximately one week for lesions in recurrent disease. Atypical manifestations are common. Infected persons experience a median of four recurrences per year after their first episode, but rates vary greatly. Genital herpes simplex virus type 2 recurs six times more frequently than type 1. Viral culture is preferred over polymerase chain reaction testing for diagnosis. Serologic testing can be useful in persons with a questionable history. Effective oral antiviral medications are available for initial, episodic, and suppressive therapy but are not a cure. There is some evidence that alternative therapies such as L-lysine, zinc, and some herbal preparations may offer some benefit. Counseling patients about the risk of transmission is crucial and helps prevent the spread of disease and neonatal complications.
Genital herpes simplex virus (HSV) infection is a recurrent, lifelong disease with no cure. HSV is an enveloped, linear, double-stranded DNA virus whose only known hosts are humans. (1) The two types of HSV (i.e., HSV-1 and HSV-2) are distinguished by antigenic differences in their envelope proteins. HSV-1 normally is associated with oral infections and HSV-2 with genital infections, but either type can infect a person anywhere on the skin. At least 50 million persons in the United States have genital HSV infection, (2) and an estimated 500,000 to 700,000 cases of symptomatic first-episode genital HSV infections occur annually. (3) There is a concerning relationship between human immunodeficiency virus (HIV) and genital HSV infection because the interaction of HSV-2 and HIV-1 may result in more efficient transmission of HIV-1 and an increased rate of HIV replication during HSV reactivation. (4) The strongest predictor for genital HSV infection is a person's number of lifetime sex partners (Table 1). (5)
The natural history of HSV infection includes acute or subclinical first-episode mucocutaneous infection, establishment of viral latency, and subsequent reactivation. The herpes virus enters the body through the skin or mucous membranes by direct sexual contact with the secretions or mucosal surfaces of an infected person. The virus multiplies at the epithelial layer and then ascends along the sensory nerve roots to the dorsal root ganglion, where it becomes latent. With reactivation, the virus travels from the dorsal root ganglion back down the nerve root to create a mucocutaneous outbreak, or it may produce no detectable symptoms. (1) Subclinical viral shedding has been documented in more than 80 percent of HSV-2-seropositive persons who report no lesions. (6) Only 10 to 25 percent of persons who are HSV-2 seropositive report a history of genital herpes, which suggests that most infected persons have unrecognized symptomatic or completely asymptomatic infections. (6) However, once patients are told of their positive antibody status, more than 50 percent identify clinically symptomatic recurrences that previously were ascribed to other conditions. (6) It is thought that viral shedding in persons who are unaware that they are infected is responsible for at least 70 percent of HSV transmission. (6)
"Classic" outbreaks of primary genital HSV infection begin with a prodrome lasting two to 24 hours that is characterized by localized or regional pain, tingling, and burning. Patients also may have constitutional symptoms such as headache, fever, inguinal lymphadenopathy, anorexia, and malaise. (7) As the disease progresses, papules, vesicles on an erythematous base, and erosions appear over hours to days. Patterns of HSV-1 and HSV-2 infection appear identical: vesicles usually are uniform in size, and the tense center umbilicates to form a depressed center. These lesions usually crust and then re-epithelialize and heal without scarring. (8) In women, ulcers can occur on the introitus, urethral meatus, labia, and perineum. In men, ulcers often appear on the shaft or glans of the penis. In both men and women, lesions may appear on the perianal area, thighs, or buttocks (7) (Figure 1).
[FIGURE 1 OMITTED]
There are two types of first-episode, clinically apparent eruptions. The first is a nonprimary clinical eruption in a patient who has been infected previously with any type of HSV. The second type is a true primary infection, which is the first HSV infection in a seronegative patient. First-episode infections have more numerous and scattered vesicles and more systemic symptoms. Approximately 80 percent of primarily infected persons develop constitutional symptoms. (7)
Primary lesions last two to six weeks and can be extremely painful, containing large quantities of infectious HSV particles. (8) Vesicles appear approximately six days after sexual contact. (8) Viral shedding lasts longer in first-episode infections, usually 15 to 16 days, and new lesions will continue to form for about 10 days after the initial infection. (9) For unknown reasons, women have more severe disease, constitutional symptoms, and complications than do men. (8,10) This may be a result of the larger affected surface area in women and the ability of the virus to spread more easily over moist surfaces. Cervical ulcerative lesions are common and are almost always associated with first-episode disease. This type of lesion can present with intermittent bleeding and vaginal discharge. Dysuria and urinary retention syndromes may occur from urethral lesions and urine contact with vulvar lesions. Up to 25 percent of women may develop aseptic meningitis. (7,10)
Systemic complications are rare in men, although a similar urinary retention pattern may occur in men with severe disease, especially if they are uncircumcised. (8) Crusts usually will not form on the moist surface under the foreskin. Perianal infection with associated proctitis is common in homosexual men. (11)
Recurrent HSV outbreaks usually are milder than the initial episode: there typically are fewer grouped lesions (Figures 2 and 3), and viral shedding occurs at a lower concentration and for a shorter duration (i.e., about three days). However, the prodromal symptoms are similar. Crusts are shed in approximately eight days to reveal a pink, re-epithelialized surface (8) (Figure 4). Atypical manifestations are common: vesicles may not form, and HSV infection may be misdiagnosed as another disease. (7) Review of a patient's chart may be useful in identifying multiple, nonspecific complaints that serve as red flags. Patients who previously tested positive for HSV-1 and are newly infected with HSV-2 are less likely to present with classic signs and symptoms. (8)
[FIGURES 2-4 OMITTED]
Antibodies for one type of HSV seem to provide partial protection against infection with the other serotype: women infected with HSV-1 have a 5 to 20 percent lower annual rate of seroconversion to HSV-2 compared with uninfected women. (12)
Recurrence rates for HSV-2 vary greatly, but the median is four recurrences per year, and the median time to first recurrence is 50 days. (13) Approximately 90 percent of patients have at least one recurrence during the first year (Table 2). (13) Patients who experience more severe primary infections (i.e., lasting 35 days or more) have recurrent episodes twice as often and with a shorter time to first recurrence. (13) Men have more recurrences than women. (13) Although HSV-1 can cause up to 33 percent of initial outbreaks, HSV-2 infections recur six times more frequently. (8) Recurrent outbreaks occur in 50 percent of patients with HSV-1, and the median time to the first recurrence is one year following primary infection. (8) Recurrences seem to continue at these rates for at least three years (8) and may become less frequent over time. Recurrences are spontaneous, but various factors such as fever; nerve or tissue damage; physical or emotional stress; exposure to heat, cold, and ultraviolet light; immunosuppression; menses; concurrent infection; fatigue; and sexual intercourse have been associated with recurrences. (7)
Autoinoculation to different areas of the body can occur (e.g., by touching an open lesion on the mouth and scratching the genital area), but this process usually is prevented by circulating antibodies. (14) Autoinoculation is most likely to occur soon after primary infection, when antibody titers are still increasing. The use of condoms has been shown to reduce transmission rates of HSV-2 significantly in susceptible women but not in men. Using condoms during Volume 72, Number 8 October 15, 2005 25 percent or more instances of sexual intercourse was associated with reduced rates of HSV transmission, which suggests that even occasional condom use can protect women from acquisition of HSV-2. (15) To be effective, the condom must completely cover lesions on an infected man.
Viral culture is an insensitive test for detection of HSV from genital ulcers but is highly sensitive for differentiating between HSV-1 and HSV-2. (8) It is a widely available test and is the preferred method for identifying HSV infection. (2) Cultures are much more productive during the vesicular or early ulcerative stages and generally are not productive more than five days after the patient becomes symptomatic. A prepackaged viral collection system--not standard cotton swabs--should be used. The vesicle, if present, should be punctured and the fluid absorbed onto the swab. The base of the lesion should be swabbed vigorously because the virus is cell-associated. The swab is then placed into the a viral system vial (one brand: Culturette) for transport. At the laboratory, specimens are inoculated into cell cultures and monitored microscopically for five to seven days to obtain maximum sensitivity.
POLYMERASE CHAIN REACTION TESTING
Polymerase chain reaction testing for HSV DNA has greater sensitivity than the traditional viral culture (sensitivity of more than 95 percent, compared with 75 percent for culture). (16,17) Its role in the diagnosis of HSV infection has not yet been well defined, most likely because of the high cost. It is used for the diagnosis of HSV encephalitis because the results are more rapid than viral culture. (2)
HSV antibodies form during the first several weeks after infection and remain indefinitely. 2 Fifty to 90 percent of adults have antibodies to HSV, but only about 30 percent have antibodies specific to HSV-2. (18) Type-specific serologic assays can be used to confirm HSV infection in persons with a questionable history or in those who have unrecognized or subclinical infections. Serologic testing also is helpful in the presence of a false-negative culture, which is common in patients with recurrent infection or healing lesions. (18) Because HSV-2 infection is almost exclusively sexually acquired, HSV-2 antibodies are consistent with an anogenital infection. However, HSV-1 antibodies may be present in anogenital and orolabial infections; they cannot be used to differentiate between infections. (2) If HSV antibodies are present, testing for other causes of genital ulcers (e.g., syphilis, chancroid) should be considered, especially in high-risk populations. It is important to ask laboratories for glycoprotein G-specific HSV serology, because some still use older assays that do not accurately distinguish HSV-1 from HSV-2. Universal screening for HSV antibodies is not recommended. (2)
Effective oral antiviral medications are available for the treatment of genital herpes (Table 3). (2,19) These agents offer clinical benefit but do not cure the disease, (2) despite early animal models (20,21) suggesting that antiviral medications may affect the long-term natural history of HSV infection. These drugs can be used for episodic treatment or long-term suppressive therapy. Acyclovir (Zovirax), a guanosine analog that inhibits viral DNA synthesis, is the oldest and most-studied medication. It has poor bioavailability and a short half-life, which necessitates frequent dosing. Valacyclovir (Valtrex), a prodrug that metabolizes to acyclovir, has better bioavailability and requires less frequent dosing than acyclovir. Famciclovir (Famvir) is a purine analog that has high bioavailability. All have rare, similar side effects, which include nausea, vomiting, headache, and diarrhea. (19)
FIRST CLINICAL EPISODE
Most patients with initial genital HSV infection should receive antiviral therapy. (2) The main goals of initial treatment are to improve symptoms and speed recovery. One study (22) of acyclovir showed that treatment decreased constitutional symptoms by three days, local pain by two days, viral shedding by seven days, time until all lesions were crusted by three days, and time until all lesions were healed by six days. All of the antiviral medications currently used to treat HSV infection have been shown to decrease by several days the time until all lesions are crusted and healed, as well as localized pain, constitutional symptoms, and viral shedding. (19)
Episodic therapy is best for HSV-infected patients who have mild and infrequent recurrences. (23) The treatment goal is to diminish symptoms and infectivity during recurrences, rather than reduce the frequency of recurrences. To be effective, treatment should be started during the prodromal phase or within one day of lesion onset; therefore, it is important that a prescription is readily available. (2) Early therapy provides a small but statistically significant benefit. (23)
Patients with frequent recurrences overwhelmingly choose suppressive therapy. (24) It is recommended for patients with more than six episodes per year, but patient preferences also should be considered. (25) Suppressive therapy reduces recurrences by 70 to 80 percent in patients who have frequent outbreaks (i.e., more than six per year), and it probably is effective in patients with fewer recurrences. (26) Long-term safety and effectiveness have been well documented in patients receiving daily therapy with acyclovir for as long as six years, and in patients who have taken valacyclovir or famciclovir for one year. (24,27,28) The development of drug resistance is rare in immunocompetent patients. (29) For the most part, treatment is well tolerated and effective and is not associated with significant side effects. Suppressive therapy has been shown to reduce the risk of transmission significantly in heterosexual, HSV-2--discordant couples, but therapy has not been shown to fully eliminate asymptomatic viral shedding. (30,31)
Few studies have compared valacyclovir or famciclovir with acyclovir for suppressive therapy, but the existing studies suggest that all have comparable clinical outcomes. (24,27) Therefore, cost and dosing frequency are important considerations in selecting a drug for prolonged treatment. (2) Because the number of outbreaks may decrease over time, interruption of therapy should be discussed at yearly intervals to assess the need for continued therapy. (2)
Intravenous acyclovir should be considered in patients with severe or disseminated disease (e.g., pneumonitis, hepatitis, central nervous system involvement). (2) The recommended intravenous dosage is 5 to 10 mg per kg every eight hours for two to seven days, or until obvious clinical improvement occurs. The patient then can be switched to oral acyclovir to complete at least 10 days of total therapy. (2)
During HSV outbreaks, patients should keep the affected area clean and dry to prevent secondary infections. Loose-fitting clothing and cotton underwear are helpful. Patients should avoid touching the lesions and should wash their hands after any contact with the sores. An ice pack or baking soda compress may be soothing. Topical acyclovir is less effective than oral acyclovir, and its use should be discouraged. (32)
Small studies have shown some benefit with the use of 1,000 mg of L-lysine given orally three times daily, (33) 125 mg per day of aspirin given orally, (34) creams or gels containing licorice root (Glycyrrhiza glabra) applied three times daily, (35) lemon balm (Melissa officinalis) applied four times daily, (36) topical zinc applied daily, (37) and 0.5 percent Aloe vera cream applied three times daily. (38) However, studies of all of these remedies must be considered preliminary until randomized controlled trials are conducted. Future treatments may include immunomodulators such as imiquimod (Aldara) and a variety of microbicides and vaccines to prevent primary infection. (39,40)
Psychosocial Implications and Counseling
Although HSV infection is a self-limited disorder, it has a tremendous impact on affected patients, and counseling is crucial to management. The principal goals of counseling are to help patients cope with the infection and to prevent sexual and perinatal transmission. (2) Informing the patient of the diagnosis can be a delicate matter; because many patients are in considerable disbelief, it may be beneficial to wait until after the initial outbreak resolves to discuss the chronic aspects of the disease. (2) Numerous resources for patients are available (Table 4). Many patients may experience a sense of loneliness and isolation, as well as anxiety, diminished self-esteem, reluctance to initiate close relationships, and fear of initiating sexual relationships and sexual expression. A minority of patients may experience a deepening depression with each recurrence, and all aspects of their lives, including job performance, may be affected. (8)
By educating the patient about the disease process, the physician can help empower the patient to manage the disease. Patient concerns usually include the severity and frequency of clinical outbreaks, sexual relationships and transmission of the disease to others, and whether the disease will affect future childbearing. (2) The Centers for Disease Control and Prevention has recommended specific messages to be addressed when counseling patients (Table 5). (2)
Figures 1 through 4 provided by Wilford Hall Medical Center, San Antonio, Texas.
Author disclosure: Nothing to disclose.
(1.) Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-53.
(2.) Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51:1-78.
(3.) Xu F, Schillinger JA, Sternberg MR, Johnson RE, Lee FK, Nahmias AJ, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002;185:1019-24.
(4.) Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001;8:46-9.
(5.) Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA 2000;283:791-4.
(6.) Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342:844-50.
(7.) Lautenschlager S, Eichmann A. The heterogeneous clinical spectrum of genital herpes. Dermatology 2001;202:211-9.
(8.) Habif TP. Clinical dermatology. 4th ed. St. Louis: Mosby, 1996:306-10.
(9.) Corey L. First-episode, recurrent, and asymptomatic herpes simplex infections. J Am Acad Dermatol 1988;18:169-72.
(10.) Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983;98:958-72.
(11.) Krone MR, Wald A, Tabet SR, Paradise M, Corey L, Celum CL. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis 2000;30:261-7.
(12.) Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
(13.) Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847-54.
(14.) Blank H, Haines HG. Experimental human reinfection with herpes simplex virus. J Invest Dermatol 1973;61:223-5.
(15.) Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-6.
(16.) Ashley RL. Genital herpes. Type-specific antibodies for diagnosis and management. Dermatol Clin 1998;16:789-93.
(17.) Koutsky LA, Stevens CE, Holmes KK, Ashley RL, Kiviat NB, Critchlow CW, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992;326:1533-9.
(18.) Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999;12:1-8.
(19.) Brown TJ, McCrary M, Tyring SK. Antiviral agents: non-antiretroviral [correction of nonantiviral] drugs [published correction appears in J Am Acad Dermatol 2002;47:972]. J Am Acad Dermatol 2002;47:581-99.
(20.) Simmons A, Field HJ. Can HSV latency be conquered by current antiviral therapies? Sex Transm Infect 1998; 74:1-2.
(21.) Mertz GJ, Benedetti J, Critchlow C, Corey L. Long-term recurrence rates of genital herpes infections after treatment of first-episode genital herpes with oral acyclovir. In: Kono R, Nakajima A. Herpes viruses and virus chemotherapy: pharmacological and clinical approaches: proceedings of the International Symposium on Pharmacological and Clinical Approaches to Herpes Viruses and Virus Chemotherapy, Oiso, Japan, 10-13 September 1984. Amsterdam and New York: Elsevier, 1985:141-4.
(22.) Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, Connor J, et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984;252:1147-51.
(23.) Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-7.
(24.) Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998;280:887-92.
(25.) Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999;75:398-402.
(26.) Whitley RJ, Gnann JW Jr. Acyclovir: a decade later [published corrections appear in N Engl J Med 1993;328:671 and 1997;337:1703]. N Engl J Med 1992;327:782-9.
(27.) Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998;178:603-10.
(28.) Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994;169:1338-41.
(29.) Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996;33:235-48.
(30.) Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
(31.) Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
(32.) Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 1982;306:1313-9.
(33.) Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A. Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. Dermatologica 1987;175:183-90.
(34.) Karadi I, Karpati S, Romics L. Aspirin in the management of recurrent herpes simplex virus infection. Ann Intern Med 1998;128:696-7.
(35.) Csonka GW, Tyrrell DA. Treatment of herpes genitalis with carbenoxolone and cicloxolone creams: a double blind placebo controlled clinical trial. Br J Vener Dis 1984;60:178-81.
(36.) Wolbling RH, Leonhardt K. Local therapy of herpes simplex with dried extract of Melissa officinalis. Phytomedicine 1994;1:25-31.
(37.) Eby GA, Halcomb WW. Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols. Med Hypotheses 1985;17:157-65.
(38.) Syed TA, Afzal M, Ashfaq Ahmad S, Holt AH, Ali Ahmad S, Ahmad SH. Management of genital herpes in men with 0.5% Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. J Dermatol Treat 1997;8:99-102.
(39.) Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30:549-66.
(40.) Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001;184:196-200.
JOHN G. BEAUMAN, MAJ, MC, USA, is a staff family physician at Evans U.S. Army Hospital, Fort Carson, Colo. He received his medical degree from the Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, Md., and completed a residency in family medicine at Womack Army Medical Center, Fort Bragg, N.C., where he served as chief resident. He is a U.S. Army flight surgeon and has been medical director for several Army air ambulance units.
Address correspondence to John G. Beauman, M.D., Evans U.S. Army Hospital, 1650 Cochrane Circle, Fort Carson, CO 80913. Reprints are not available from the author.
COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group